TriMas Life Sciences Expands Its Cleanroom Capabilities
19 December 2023 - 6:00AM
Business Wire
Positions Company for Growth in Medical
Technology Applications
TriMas (NASDAQ: TRS) today announced that its Intertech
business, part of the TriMas Life Sciences division, has expanded
its cleanroom capacity at its Denver, Colorado, facility. The
additional production space addresses increased customer demand for
highly engineered components used in medical technology
applications, such as for use in testing, vascular delivery and
extraction applications.
Intertech recently expanded its ISO Class 8 cleanroom molding
and assembly capacity by an additional 3,400 square feet, including
dedicated space for molding presses and secondary operation
equipment. The addition complements Intertech’s existing 9,000-plus
square feet of ISO Class 8 cleanroom capacity. In addition, TriMas
has invested in additional cleanroom capabilities at a second
facility in the Denver area, under Intertech’s existing ISO 13485
Medical Devices Quality Management Systems certification.
“Our increased investments in the Life Sciences end market
continue to be an important long-term strategic enhancement for
TriMas,” commented Thomas Amato, TriMas President and Chief
Executive Officer. “By expanding our cleanroom production
capabilities, we are addressing the growing demand needs of our
customers, while remaining at the forefront of stringent regulatory
standards. This investment not only underscores our dedication to
operational excellence and superior quality, but also reaffirms our
commitment to serving the evolving needs of the Life Sciences
sector.”
In addition to its certified ISO Class 8 cleanroom environments,
Intertech’s manufacturing facility, located in Denver, Colorado, is
also MedAccred® accredited.
The TriMas Life Sciences division, which is comprised of the
Intertech and Omega businesses, as well as certain pharmaceutical
and nutraceutical product lines, manufactures complex, precision
injection molded components and assemblies for applications in the
Life Sciences end market. TriMas Life Sciences’ capabilities and
products include rapid prototype capability, as well as production
molds, and custom, medical-related components such as consumable
vascular delivery, patient monitoring and diagnostic test
components, surgical devices, pharmaceutical airless dispensers and
nutraceutical closures. TriMas Life Sciences collaborates with
clients to deliver safe, compliant and “part perfect” products and
components that positively impact people’s lives. For more
information, please visit www.trimaslifesciences.com.
About TriMas
TriMas manufactures a diverse set of products primarily for the
consumer products, aerospace and industrial markets through its
TriMas Packaging, TriMas Aerospace and Specialty Products groups.
Our approximately 3,500 dedicated employees in 13 countries provide
customers with a wide range of innovative and quality product
solutions through our market-leading businesses. Our TriMas family
of businesses has strong brand names in the markets served, and
operates under a common set of values and strategic priorities
under the TriMas Business Model. TriMas is publicly traded on the
NASDAQ under the ticker symbol “TRS,” and is headquartered in
Bloomfield Hills, Michigan. For more information, please visit
www.trimas.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231218421009/en/
Sherry Lauderback VP, Investor Relations & Communications
(248) 631-5506 sherry.lauderback@trimas.com
TriMas (NASDAQ:TRS)
Historical Stock Chart
From Apr 2024 to May 2024
TriMas (NASDAQ:TRS)
Historical Stock Chart
From May 2023 to May 2024